Dr. Berry on LHRH Antagonists Versus Agonists for Prostate Cancer

William R. Berry, MD
Published: Tuesday, Oct 31, 2017



William R. Berry, MD, medical oncologist, Duke University, discusses determining when to use luteinizing hormone-releasing hormone (LHRH) antagonists versus agonists for patients with prostate cancer.

Before LHRH antagonists, there was a concern for patients who presented with metastatic disease, particularly metastatic disease in the bone, states Berry. Many of these patients would experience a surge of bone pain after starting therapy.

There is an indication to use the antagonist as they present with fewer symptoms than agonists, explains Berry.
 


William R. Berry, MD, medical oncologist, Duke University, discusses determining when to use luteinizing hormone-releasing hormone (LHRH) antagonists versus agonists for patients with prostate cancer.

Before LHRH antagonists, there was a concern for patients who presented with metastatic disease, particularly metastatic disease in the bone, states Berry. Many of these patients would experience a surge of bone pain after starting therapy.

There is an indication to use the antagonist as they present with fewer symptoms than agonists, explains Berry.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x